Innovative PDK1‐Degrading PROTACs Transform Cancer Aerobic Glycolysis and Induce Immunogenic Cell Death in Breast Cancer
ABSTRACT Cancer cells are characterized by the Warburg effect, which hijacks glycolysis and hinders OXPHOS. Pyruvate dehydrogenase kinase 1 (PDK1) is a key modulator in the Warburg effect and is highly expressed in tumor cells. We utilize PROTAC technology to design compounds that could achieve long...
Saved in:
| Main Authors: | Aohua Deng, Renming Fan, Jiakui Gou, Ruoxi Sang, Ruizhuo Lin, Ting Zhao, Junyan Zhuang, Yongrui Hai, Jialin Sun, Gaofei Wei |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Exploration |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/EXP.20240031 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
by: Zhao K, et al.
Published: (2025-06-01) -
PIWIL2/PDK1 Axis Promotes the Progression of Cervical Epithelial Lesions via Metabolic Reprogramming to Maintain Tumor‐Initiating Cell Stemness
by: Yuebo Li, et al.
Published: (2024-12-01) -
MiR‐5683 suppresses glycolysis and proliferation through targeting pyruvate dehydrogenase kinase 4 in gastric cancer
by: Yongchang Miao, et al.
Published: (2020-10-01) -
PROTACs for BRDs proteins in cancer therapy: a review
by: Chao Wang, et al.
Published: (2022-12-01) -
PROTAC Technology as a New Tool for Modern Pharmacotherapy
by: Natalia Kubryń, et al.
Published: (2025-05-01)